Compare · BIIB vs HLVX
BIIB vs HLVX
Side-by-side comparison of Biogen Inc. (BIIB) and HilleVax Inc. (HLVX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and HLVX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB carries a market cap of $30.41B.
- Over the past year, BIIB is up 67.9% and HLVX is up 1.7% - BIIB leads by 66.2 points.
- BIIB has hit the wire 14 times in the past 4 weeks while HLVX has been quiet.
- BIIB has more recent analyst coverage (25 ratings vs 6 for HLVX).
- Company
- Biogen Inc.
- HilleVax Inc.
- Price
- $206.02-1.49%
- $2.10-0.71%
- Market cap
- $30.41B
- -
- 1M return
- +5.35%
- +1.21%
- 1Y return
- +67.92%
- +1.70%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 6
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
HilleVax Inc.
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Latest BIIB
- Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
- Biogen Appoints Michael J. Parini as Chief Legal Officer
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
- Biogen upgraded by Truist with a new price target
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
- LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
Latest HLVX
- SEC Form 15-12G filed by HilleVax Inc.
- SEC Form EFFECT filed by HilleVax Inc.
- SEC Form EFFECT filed by HilleVax Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by HilleVax Inc.
- SEC Form 4 filed by Large owner Takeda Pharmaceutical Co Ltd
- Amendment: SEC Form SCHEDULE 13D/A filed by HilleVax Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by HilleVax Inc.
- SEC Form 4 filed by Large owner Frazier Life Sciences X, L.P.
- SEC Form S-8 POS filed by HilleVax Inc.
- SEC Form POS AM filed by HilleVax Inc.